In a report released on October 8, Leonid Timashev from RBC Capital maintained a Buy rating on Nuvation Bio. The company’s shares closed yesterday at $3.75.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Timashev covers the Healthcare sector, focusing on stocks such as Alkermes, Insmed, and Axsome Therapeutics. According to TipRanks, Timashev has an average return of 22.4% and a 57.65% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Nuvation Bio with a $9.17 average price target, which is a 144.53% upside from current levels. In a report released on September 29, Jefferies also initiated coverage with a Buy rating on the stock with a $10.00 price target.
The company has a one-year high of $4.09 and a one-year low of $1.54. Currently, Nuvation Bio has an average volume of 5.86M.
Read More on NUVB:
Disclaimer & DisclosureReport an Issue
- Nuvation Bio enrolls first patient in TRUST-IV Phase 3 study of IBTROZI
- Nuvation Bio’s Strategic Growth Potential and Promising Pipeline Justify Buy Rating
- Nuvation Bio initiated with a Buy at Jefferies
- Nuvation Bio announces Japan MHLW approval for Ibtrozi
- Nuvation Bio’s Phase 3 Study on Taletrectinib: A Potential Game-Changer for NSCLC Treatment
/Super%20Micro%20Computer%20Inc%20logo%20on%20building-by%20Poetra_RH%20via%20Shutterstock.jpg)
